Product nameAAL 993, VEGFR inhibitor
DescriptionPotent, selective and cell-permeable VEGFR inhibitor
Biological descriptionPotent, selective and cell-permeable VEGFR inhibitor (IC50 values are 130, 23 and 18 nM for VEGFR1, 2, and 3 respectively). Inhibits VEGF-induced angiogenesis in vivo. Suppresses hypoxia-induced HIF-1α expression without affecting Akt phosphorylation in vitro.
Storage instructionsStore at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.
Solubility overviewSoluble in ethanol to 25 mM and in DMSO to 50 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
- Receptors & Transporters
- Enzyme-Linked Receptors
- Receptor tyrosine kinases
This product has been referenced in:
- Ban HS et al. Suppression of hypoxia-induced HIF-1alpha accumulation by VEGFR inhibitors: Different profiles of AAL993 versus SU5416 and KRN633. Cancer Lett 296:17-26 (2010). Read more (PubMed: 20378243) »
- Manley PW et al. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim Biophys Acta 1697:17-27 (2004). Read more (PubMed: 15023347) »
- Manley PW et al. Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem 45:5687-93 (2002). Read more (PubMed: 12477352) »